To examine the potential role of remimazolam besylate in modern ICU sedation practices and identify the pharmacological and clinical uncertainties that limit its definitive positioning.
Approach:
Key Findings:
Remimazolam is rapidly hydrolysed by CES1, offering a potentially predictable recovery profile.
Clinical studies suggest remimazolam achieves sedation comparable to propofol and dexmedetomidine, but efficacy may not be as predictable as assumed.
Remimazolam may have a favorable haemodynamic profile, showing lower rates of hypotension and bradycardia compared to other sedatives.
No robust data currently support remimazolam's impact on delirium or long-term cognitive outcomes.
Concerns remain regarding prolonged infusion and its effects on plasma concentrations and awakening.
Interpretation:
Remimazolam's role in ICU sedation is not yet fully established, and its advantages in specific patient populations require further investigation.
Limitations:
Current evidence is primarily from Asian cohorts, which may not reflect global practices.
Pharmacodynamic variability in critically ill patients complicates dosing strategies.
Lack of robust data on long-term outcomes and delirium in ICU settings.
Conclusion:
Remimazolam shows promise in critical care sedation, but its definitive role and existing uncertainties need further exploration.
